Literature DB >> 2227113

Insulinlike activity of new antidiabetic agent CP 68722 in 3T3-L1 adipocytes.

D K Kreutter1, K M Andrews, E M Gibbs, N J Hutson, R W Stevenson.   

Abstract

We examined the in vitro effects of CP 68722, a novel antidiabetic agent, in 3T3-L1 adipocytes. CP 68722 stimulated 2-deoxyglucose uptake in the absence of insulin. At least 30 min of incubation were required for stimulation of uptake. This effect increased over 5 h and was sustained up to 72 h. The stimulation of 2-deoxyglucose uptake by CP 68722 could be inhibited approximately 60% by inhibition of protein synthesis with cycloheximide. Half-maximal and maximal responses to CP 68722 at 72 h of incubation were observed at 10 and 100 microM of drug, respectively, with a threefold stimulation of uptake at 100 microM approximating the maximal response of these cells to acute insulin stimulation. CP 68722 was able to overcome insulin resistance induced by dexamethasone in 3T3-L1 cells. The effect of drug, like that of insulin, was primarily to increase the Vmax of 2-deoxyglucose uptake. The stimulation of uptake by CP 68722 or insulin could be prevented by incubating the cells at 10 degrees C, a temperature that impedes translocation of glucose transporters to the plasma membrane. Therefore, it appears that CP 68722, like insulin, stimulates glucose uptake by a mechanism that involves translocation of intracellular glucose transporters to the plasma membrane and de novo protein synthesis. We compared the effect of CP 68722 with the sulfonylureas, the primary drugs used in the treatment of non-insulin-dependent diabetes mellitus (NIDDM). CP 68722 was a more potent and effective stimulator of 2-deoxyglucose uptake in 3T3-L1 cells than either first- or second-generation sulfonylureas.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2227113     DOI: 10.2337/diab.39.11.1414

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  8 in total

1.  Acute troglitazone action in isolated perfused rat liver.

Authors:  K Preininger; H Stingl; R Englisch; C Fürnsinn; J Graf; W Waldhäusl; M Roden
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

2.  Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling.

Authors:  P Peraldi; M Xu; B M Spiegelman
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

3.  Troglitazone prevents and reverses dexamethasone induced insulin resistance on glycogen synthesis in 3T3 adipocytes.

Authors:  K L Anil Kumar; A R Marita
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

4.  Chronic and acute effects of thiazolidinediones BM13.1258 and BM15.2054 on rat skeletal muscle glucose metabolism.

Authors:  C Fürnsinn; B Brunmair; M Meyer; S Neschen; R Furtmüller; M Roden; H F Kühnle; P Nowotny; B Schneider; W Waldhäusl
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

Review 5.  Troglitazone: a review of its use in the management of type 2 diabetes mellitus.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1999-03       Impact factor: 9.546

6.  Effect of a novel non-thiazolidinedione peroxisome proliferator-activated receptor alpha/gamma agonist on glucose uptake.

Authors:  X Hu; Y Feng; X Liu; X-F Zhao; J-H Yu; Y-S Yang; M Sydow-Bäckman; J Hörling; J R Zierath; Y Leng
Journal:  Diabetologia       Date:  2007-03-01       Impact factor: 10.122

7.  Metabolic effects of darglitazone, an insulin sensitizer, in NIDDM subjects.

Authors:  R L Chaiken; M Eckert-Norton; R Pasmantier; G Boden; I Ryan; R A Gelfand; H E Lebovitz
Journal:  Diabetologia       Date:  1995-11       Impact factor: 10.122

8.  Insulin sensitizing effect of 3 Indian medicinal plants: an in vitro study.

Authors:  Samidha A Kalekar; Renuka P Munshi; Supriya S Bhalerao; Urmila M Thatte
Journal:  Indian J Pharmacol       Date:  2013 Jan-Feb       Impact factor: 1.200

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.